

## Special Issue

# Cellular and Viral Immunology of HIV-1 Infection

### Message from the Guest Editors

The human immunodeficiency virus (HIV) continues to be a global threat since its emergence in 1981. Even though an enormous amount of research has been carried out to understand the life cycle of the virus, HIV remains a mystery. There is currently no effective cure, but with proper medical care, HIV can be controlled. If left untreated, it can lead to AIDS (acquired immunodeficiency syndrome). HIV attacks and weakens the body's immune system. It evades T4 lymphocyte, which is the key component for generating and regulating the immune response, and many other cell types, such as monocytes/macrophages. HIV uses its envelope glycoprotein binds to host cell receptors CD4 and CCR5/CXCR4, driving the virus' entry into host cells to further replicate and transmit using the host cell machinery. It is imperative that studies on HIV continue and are shared. This Special Issue is focused on the recent advances made in this field. We invite you to contribute with an original report or review to highlight the Cellular and Viral Immunology of HIV-1 Infection.

### Guest Editors

Dr. Saumya Anang

Microbiology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave., Boston, MA 02215, USA

Dr. Qian Wang

Irving Medical Center, Columbia University, 701 W. 168 St, 11th Floor, New York, NY 10032, USA

### Deadline for manuscript submissions

closed (12 January 2024)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/164767](https://mdpi.com/si/164767)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[vaccines](https://vaccines.mdpi.com)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).